AI assistant
Entrada Therapeutics, Inc. — Director's Dealing 2021
Oct 29, 2021
33674_dirs_2021-10-28_633d52fc-93e2-4fed-9c61-4a25cdd83729.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Entrada Therapeutics, Inc. (TRDA)
CIK: 0001689375
Period of Report: 2021-10-28
Reporting Person: Crowley John F (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 32864 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $8.47 | 2031-05-20 | Common Stock (14180) | Direct |
Footnotes
F1: Consists of (i) 19,170 shares of common stock and (ii) 13,694 shares of restricted common stock issued upon early exercise of stock options held by John F. Crowley 2021 Family Trust. John F. Crowley exercises voting and dispositive power over the shares beneficially owned by John F. Crowley 2021 Family Trust.
F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments, commencing on March 30, 2021 (the "Vesting Start Date"), such that the option shares will be fully vested on the four-year anniversary of the Vesting Start Date.